Drug intelligence / Profile preview

BMS-986463

Development stage: Phase 1
Lead developer: Bristol Myers Squibb

Overview

BMS-986463 is an investigational drug developed by Bristol Myers Squibb for the treatment of advanced malignant tumors and solid tumors. It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and efficacy in patients with unresectable or metastatic carcinomas. The precise mechanism of action and molecular target have not been publicly disclosed as of June 2025. Indications under investigation include non-small cell lung cancer, high grade serous adenocarcinoma of the ovary, uterine cancer, and other advanced cancers[2][3][7][9].

Beyond the preview

Go deeper on BMS-986463.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986463.

Explore the full profile